Spectrum data suggests strong connection between satraplatin and Taxotere, Herceptin

By Elaine Rigoli

Tampa, Fla., April 3 - Spectrum Pharmaceuticals, Inc. announced new preclinical data on its lead drug candidate satraplatin in a variety of combination therapies and cancer settings, including in-vivo studies evaluating the efficacy of satraplatin and Taxotere (docetaxel), both individually and in combination, using various dosing and treatment schedules.

Within the range of doses and schedules tested, a combination of the two compounds administered sequentially results in therapeutically synergistic effects - superior to the best result that could be obtained with either agent administered individually - with no apparent increase in toxicity compared to either single agent in this tumor model, according to a news release.

Another study evaluated satraplatin's active metabolite, JM118, in combination with Herceptin (trastuzumab) against SKBR-3 breast cancer cells, which are known to be sensitive to Herceptin, the release said.

The data showed that, within the range of doses and schedules tested, both concurrent and sequential exposure of the cells to these two compounds resulted in strong synergistic cytotoxic activity.

Currently a phase 2 trial evaluating satraplatin in patients with metastatic breast cancer is underway, the release said. This study is being conducted to gain more insight into the activity of satraplatin in this important cancer area.

Spectrum is a specialty pharmaceutical company located in Irvine, Calif.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.